Background Low skeletal muscle mass (LSMM) and/or, function associated with an
increased risk of treatment‐related toxicities and inferior overall survival (OS) among adults …

Background & aims Evidence regarding the prevalence of pre-treatment sarcopenia and its
impact on survival in patients with hematological malignancies (HM) varies across studies …

Simple Summary The effective role of sarcopenia and body changes during treatment in
elderly (> 65 years) Hodgkin lymphoma (HL) is unclear. The aim of our study was to analyze …

Sarcopenia is considered to be a poor prognostic factor for several oncological diseases;
however, some promising results for lymphoma are now available. The definition of …

Measures of muscle and adipose tissue mass have been associated with outcomes in
several malignancies, but studies in multiple myeloma (MM) are inconsistent. The aim of this …

Autologous hematopoietic stem cell transplantation (ASCT) improves survival for patients
with chemotherapy-sensitive lymphoma. Validated scoring systems are used in the clinical …

Introduction Skeletal muscle function is an important prognostically relevant indicator in
patients with acute leukemia (AL), but skeletal dysfunction during chemotherapy is not well …

Findings regarding the relationship between sarcopenia and lymphoma have been
inconsistent across studies. This study investigated the association between sarcopenia and …

Introduction Poor skeletal muscle function is relatively high in patients undergoing
allogeneic hematopoietic stem cell transplantation (allo-HSCT), leading to various negative …

Recently there has been a growing interest in evaluating body composition as a marker for
prognosis in cancer patients. The association of body composition parameters and …